Natera, Inc. (NASDAQ:NTRA) CFO Sells $7,694,633.76 in Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 43,502 shares of the stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $176.88, for a total value of $7,694,633.76. Following the sale, the chief financial officer now directly owns 70,629 shares in the company, valued at $12,492,857.52. This trade represents a 38.12 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Michael Burkes Brophy also recently made the following trade(s):

• On Wednesday, January 29th, Michael Burkes Brophy sold 4,335 shares of Natera stock. The shares were sold at an average price of $165.87, for a total value of $719,046.45.
• On Friday, January 31st, Michael Burkes Brophy sold 1,886 shares of Natera stock. The shares were sold at an average price of $176.60, for a total transaction of $333,067.60.
• On Monday, January 27th, Michael Burkes Brophy sold 1,442 shares of Natera stock. The stock was sold at an average price of $161.87, for a total transaction of $233,416.54.
• On Friday, January 24th, Michael Burkes Brophy sold 946 shares of Natera stock. The shares were sold at an average price of $171.98, for a total transaction of $162,693.08.
• On Wednesday, January 22nd, Michael Burkes Brophy sold 25,931 shares of Natera stock. The stock was sold at an average price of $164.97, for a total transaction of $4,277,837.07.

Natera Trading Down 1.3 %

Shares of NASDAQ:NTRA traded down $2.32 on Tuesday, reaching $174.24. 1,124,858 shares of the company traded hands, compared to its average volume of 1,398,383. The stock has a market capitalization of $23.00 billion, a P/E ratio of -99.00 and a beta of 1.66. The business’s 50-day simple moving average is $167.26 and its 200 day simple moving average is $139.52. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. Natera, Inc. has a 52 week low of $66.68 and a 52 week high of $183.00.

Natera (NASDAQ:NTRA) last announced its quarterly earnings results on Tuesday, November 12th. The medical research company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.31. The business had revenue of $439.80 million for the quarter, compared to analysts’ expectations of $361.43 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The business’s quarterly revenue was up 63.9% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.95) EPS. As a group, equities analysts anticipate that Natera, Inc. will post -1.56 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently commented on NTRA. TD Cowen boosted their target price on Natera from $155.00 to $175.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. The Goldman Sachs Group boosted their price objective on Natera from $160.00 to $190.00 and gave the stock a “buy” rating in a report on Tuesday, January 28th. Canaccord Genuity Group raised their target price on shares of Natera from $165.00 to $180.00 and gave the company a “buy” rating in a research note on Friday, January 3rd. Sanford C. Bernstein lifted their target price on shares of Natera from $160.00 to $200.00 and gave the company an “outperform” rating in a research report on Friday, January 10th. Finally, Piper Sandler increased their price target on shares of Natera from $150.00 to $200.00 and gave the stock an “overweight” rating in a report on Monday, November 18th. One equities research analyst has rated the stock with a sell rating and seventeen have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $165.88.

Institutional Investors Weigh In On Natera

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Chartwell Investment Partners LLC increased its stake in shares of Natera by 37.9% during the third quarter. Chartwell Investment Partners LLC now owns 41,302 shares of the medical research company’s stock valued at $5,243,000 after buying an additional 11,362 shares during the period. Cerity Partners LLC boosted its holdings in Natera by 27.0% in the third quarter. Cerity Partners LLC now owns 86,144 shares of the medical research company’s stock valued at $10,936,000 after acquiring an additional 18,316 shares in the last quarter. Wilmington Savings Fund Society FSB purchased a new position in Natera during the 3rd quarter valued at $385,000. Everence Capital Management Inc. bought a new position in Natera in the 4th quarter worth $573,000. Finally, First Turn Management LLC purchased a new stake in shares of Natera in the 3rd quarter worth about $19,760,000. 99.90% of the stock is currently owned by institutional investors.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.